News - Page 359

TLDR: Private equity and venture capital offer diverse investment opportunities Retail traders can access private equity through specific assets When nested within a diverse portfolio, private equity and venture capital investments provide

TLDR: The Latin American Private Equity and Venture Capital Association reported a liquidity “drought” in Q1 with limited investment exits. Brazil’s communications ministry will release resources to support telecom operators in flood-devastated

TLDR: AltC Acquisition Corp. merges with Oklo Inc., a green fission power technology innovator. Oklo will become publicly traded, giving investors a chance to invest in sustainable energy solutions. AltC Acquisition Corp.

TLDR: URCSI, a Canadian PropTech Company, partners with Capital Q Ventures Inc., a leader in alternative investment fund management. Capital Q Ventures Inc. takes a 5% equity stake and commits an additional

TLDR: Private equity and venture capital investments in India dipped by 35% in 2023, with total investments at around $39 billion compared to $62 billion in 2022. Private equity investments dropped by

TLDR: Starshot Capital has closed its 12th climate fund of the year, contributing to a total of $3.5 billion raised by a dozen climate-focused venture funds in 2023. Key points: Starshot Capital

TLDR: Article discusses the impact of climate change on global food security Highlights the need for immediate action to mitigate the effects of climate change In a recent article on MSN, the

TLDR: Benson Hill Inc. hires a former in-house counsel to help with management and financial shakeup The new general counsel has a background in venture capital and will assist in the company’s

TLDR: Sikich, a technology-enabled professional services company based in Chicago, received a $250M minority growth investment from Bain Capital. The investment will be used to accelerate value creation and development efforts. Sikich,

TLDR: Bluejay Therapeutics, a company focused on developing novel therapeutics, raised $182M in Series C funding. The funding will be used to accelerate the clinical development of BJT-778 for chronic hepatitis D